The concomitant use of anticholinergic drugs with Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus [ Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL can cause you to be drowsy, slow your thinking and motor skills, and affect your vision. 8600 Rockville Pike, Bethesda, MD, 20894 USA. Each teaspoonful (5 mL) for oral administration contains: Hydrocodone Bitartrate and Homatropine Methylbromide Syrup also contains: Caramel color, cherry flavor, citric acid, FD&C Red #40, methylparaben, propylparaben, purified water, sorbitol solution and sucrose syrup. Do not abruptly discontinue Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in a physically-dependent patient [, Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL contains hydrocodone, a Schedule II controlled substance. see Hydrocodone bitartrate and homatropine methylbromide should be given with caution to certain patients such as the elderly or debilitated, and those with severe impairment of hepatic or renal functions, hypothyroidism, Addisons disease, prostatic hypertrophy or urethral stricture, asthma, and narrow-angle glaucoma. Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL contains hydrocodone, an opioid (narcotic) cough suppressant. I am just having a hard time figuring out at what dosage the Homatropine Methylbromide will start to make me feel ill, if at all. Presence in Breast Milk, Medline Plus, The effects of hydrocodone in therapeutic doses on the cardiovascular system are insignificant. Events, (What FDA Safety Recalls, ]. Overdose of hydrocodone in adults has been associated with fatal respiratory depression, and the use of hydrocodone in children younger than 6 years of age has been associated with fatal respiratory depression when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. The dosage of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL should not be increased if cough fails to respond; an unresponsive cough should be reevaluated for possible underlying pathology [ MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma). Store Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL at room temperature between 68F to 77F (20C to 25C). This can cause symptoms such as shortness of breath, slow and shallow breathing, and bluish-colored lips, fingers, or toes. HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE syrup, 0121-4811-05, Assess each patient's risk prior to prescribing Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL, prescribe Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL for the shortest duration that is consistent with individual patient treatment goals, monitor all patients regularly for the development of addition or abuse, and refill only after reevaluation of the need for continued treatment [ HOMATROPINE METHYLBROMIDE USP (55-1007) View SDS. If you do not have one, ask your pharmacist to give you a measuring device to help you measure the correct amount of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL. Hydrocodone causes miosis, even in total darkness. Warnings and Precautions (5.4)]. In patients with circulatory shock, Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL may cause vasodilation that can further reduce cardiac output and blood pressure. Take Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL exactly as your healthcare provider tells you to take it. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting and fever. "Doctor shopping" (visiting multiple prescribers to obtain additional prescriptions) is common among drug abusers and people suffering from untreated addiction. Patients with severe hepatic impairment may have higher plasma concentrations than those with normal hepatic function [ Use of Hydrocodone bitartrate and homatropine methylbromide syrup in children less than 6 years of age has been associated with fatal respiratory depression. Warnings and Precautions (5.2)]. The concomitant use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL and CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, can decrease the plasma concentration of hydrocodone [ Measure Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL oral solution with an accurate milliliter measuring device. RxNorm, see Associates, Inc. Hydrocodone produces peripheral vasodilation which may result in orthostatic hypotension or syncope. see View NDC Code(s)NEW! see Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL contains hydrocodone, an opioid agonist; and homatropine, a muscarinic antagonist. Hydrocodone bitartrate and homatropine methylbromide syrup may produce dose-related respiratory depression by acting directly on brain stem respiratory centers (See OVERDOSAGE). Advise the patient to read the FDA-approved patient labeling (Medication Guide). If concomitant use is necessary, monitor patients for respiratory depression and sedation at frequent intervals. see Concomitant use of alcohol with Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL can result in an increase of hydrocodone plasma levels and potentially fatal overdose of hydrocodone. Save money on your Hycodan Syrup [CII] prescription by switching to Teva's FDA-approved generic version, Hydromet Syrup (Hydrocodone Bitartrate and Homatropine Methylbromide Syrup) CII We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience. Patient Counseling Information (17)]. Warnings and Precautions (5.9), Respiratory depression is the chief risk for elderly patients treated with opioids, including Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL. see see 1.5 mg That would match with the effect I am getting from the hydrocodone at a 30mL dose. ORAL SOLUTION Warnings and Precautions (5.8), ]. If concomitant use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL with a CYP3A4 inhibitor or inducer is necessary, monitor patients for signs and symptoms that may reflect opioid toxicity and opioid withdrawal [, Concomitant use of opioids, including Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL, with benzodiazepines, or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reevaluate patients with unresponsive cough in 5 days or sooner for possible underlying pathology, such as foreign body or lower respiratory tract disease [ 1), Important Limitations of Use ( Because the benefits of symptomatic treatment of cough associated with allergies or the common cold do not outweigh the risks of use of hydrocodone in pediatric patients, Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is not indicated for use in patients younger than 18 years of age [ Department of Health and Human Services. "Drug-seeking" behavior is very common in persons with substance use disorders. Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations. Citric acid and/or sodium citrate may be added to adjust pH. See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. see There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) [ In animal reproduction studies, hydrocodone administered by the subcutaneous route to pregnant hamsters during the period of organogenesis produced a teratogenic effect at a dose approximately 45 times the maximum recommended human dose (MRHD) ( Avoid starting Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL if you stopped taking an MAOI in the last 14 days. Inactive ingredients in Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL oral solution: hydrocodone bitartrate and homatropine methylbromide syrup, All Drug Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. ]. Warnings and Precautions (5.1), Avoid the use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in patients taking benzodiazepines, other CNS depressants, or alcohol [ Overdose and death due to medicine dosing errors. Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Keep Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL and all medicines out of the reach of children. hydrocodone bitart-homatropine methylbromide tab 5-1.5 mg 2 hydromet syp 5-1.5/52 prometh vc syp 6.25-5/52 promethazine w/ codeine syrup 6.25-10 mg/5ml 2 promethazine-dm syrup 6.25 15 mg/5ml2 promethazine-phenylephrine codeine syrup 6.25-5-10 mg/5ml 2 pseudoephed-bromphen dm syrup 30 210 mg/5ml TUXARIN ER TAB 54.3-8MG 4 TUZISTRA XR SUS4 This material is not classified dangerous good according to international transportation regulations (ADR/RID-IMDG-ICAO/IATA). An antagonist should not be administered in the absence of clinically significant respiratory depression. Drug Interactions (7.6)]. Advise patients how to recognize respiratory depression and to seek medical attention if breathing difficulties develop. see Clinical Pharmacology (12.3)]. The concomitant use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is not recommended for use in pregnant women. Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is a combination of hydrocodone, an opioid agonist; and homatropine, a muscarinic antagonist, indicated for the symptomatic relief of cough in patients 18 years of age and older. HYCODAN (hydrocodone bitartrate and homatropine methylbromide) is indicated for the symptomatic relief of cough in adults and children 6 years of age and older. When hydrocodone is used for a long time, it may become habit-forming, causing mental or physical dependence. We recognize our responsibility and see it as an opportunity to improve lives and to make a lasting social impact. Do not increase the dose or dosing frequency. No evidence of tumorigenicity was observed in male and female mice at codeine dietary doses up to 400 mg/kg/day (approximately equivalent to 110 times the MRHD of hydrocodone on a mg/m Dosage and Administration (2.1), Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control. (, Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of hydrocodone. Hycodan (hydrocodone bitartrate and homatropine methylbromide) is a combination of a narcotic cough medicine and a medicine that works against the narcotic to prevent an overdose used to treat cough. No information is available on the effects of hydrocodone on milk production. Tell your healthcare provider if your cough does not get better within 5 days of treatment with Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL. Warnings and Precautions (5.8), Published in vitro studies have shown that N-demethylation of hydrocodone to form norhydrocodone can be attributed to CYP3A4 while O-demethylation of hydrocodone to hydromorphone is predominantly catalyzed by CYP2D6 and to a lesser extent by an unknown low affinity CYP enzyme. Homatropine methylbromide ( INN; also known as methylhomatropine bromide) is a quaternary ammonium salt of methylhomatropine. Drug Interactions (7.1)]. as between 15mg and 40mg. Hydromorphone is formed from the O-demethylation of hydrocodone and may contribute to the total analgesic effect of hydrocodone. Rx ONLY, Pkg. Warnings and Precautions (5.6)]. Benzhydrocodone is a hydrocodone prodrug that is rapidly converted into hydrocodone in the gastrointestinal tract. Use in Specific Populations (8.3)]. Elderly, Cachectic, or Debilitated Patients: Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients [ see What Are Side Effects of Hycodan? Benefit to risk ratio should be carefully considered especially in the pediatric population with respiratory embarrassment (e.g., croup). Boxed WARNINGS ( Dosing errors can result in accidental overdose and death. Monitor neonates exposed to opioids during labor for signs of excess sedation and respiratory depression. Sedation, drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, dizziness, psychic dependence, mood changes. see Known or suspected gastrointestinal obstruction, including paralytic ileus. (, Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Do not overfill. What are the ingredients in Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL? Patients must not consume alcoholic beverages, or prescription or non-prescription products containing alcohol, while on Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL therapy. These side-effects are possible, but do not always occur. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL. Hydrocodone and homatropine combination is used to relieve cough in adults and children 6 years of age and older. Monitor closely, especially upon initiation or when used in patients at higher risk. Following a 10 mg oral dose of hydrocodone administered to five adult male subjects, the mean peak concentration was 23.6 5.2 ng/mL. ]. Homatropine methylbromide is included in a subtherapeutic amount to discourage deliberate overdosage. Accidental ingestion of even one dose of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL, especially by children, can result in respiratory depression and death. Advise both patients and caregivers about the risks of respiratory depression and sedation if Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is used with benzodiazepines, alcohol, or other CNS depressants [, Patients must not consume alcoholic beverages, or prescription or non-prescription products containing alcohol, while on Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL therapy. Cardiovascular: Peripheral edema, increased blood pressure, decreased blood pressure, tachycardia, chest pain, palpitation, syncope, orthostatic hypotension, prolonged QT interval, hot flush. After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the hydrocodone plasma concentration will decrease [ Warnings and Precautions (5.2), Citations, 2.1 Important Dosage and Administration Instructions, 2.3 Monitoring, Maintenance, and Discontinuation of Therapy, 5.2 Life-Threatening Respiratory Depression, 5.3 Risks with Use in Pediatric Populations, 5.4 Risks with Use in Other At-Risk Populations, 5.5 Risk of Accidental Overdose and Death due to Medication Errors, 5.6 Activities Requiring Mental Alertness: Risks of Driving and Operating Machinery, 5.7 Risks from Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers, 5.8 Risks from Concomitant Use with Benzodiazepines or other CNS Depressants, 5.9 Risks of Use in Patients with Gastrointestinal Conditions, 5.10 Risks of Use in Patients with Head Injury, Impaired Consciousness, Increased Intracranial Pressure, or Brain Tumors, 5.11 Increased Risk of Seizures in Patients with Seizure Disorders, 7.4 Benzodiazepines, and Other CNS Depressants, 8.3 Females and Males of Reproductive Potential, 13.1 Carcinogenesis Mutagenesis and Impairment of Fertility, Report Adverse 7.4)]. Drug Interactions (7.1, View the latest press releases, feature stories, and company resources. Maximum serum levels were achieved at 1.3 0.3 hours. Inform patients that the use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death [ Use in Specific Populations (8.2)]. ]. see Instruct patients how to measure and take the correct dose of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL. Product name: Hydrocodone Bitartrate and Homatropine Methylbromide Syrup Other means of identification Product code(s): 0121-4811-05 UN-Number: NA Synonyms: Compare to Tussigon Recommended use of the chemical and restrictions on use Recommended use: Pharmaceutical product used as a narcotic antitussive analgesic If Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is prescribed, monitor such patients closely, particularly when initiating Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL and when Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is given concomitantly with other drugs that depress respiration [ In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. see Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated "loss" of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating health care provider(s). Avoid the use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in patients taking benzodiazepines, other CNS depressants, or alcohol [, Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products that contain alcohol while taking Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL. Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral narcotic use, although some mild degree of physical dependence may develop after a few days of narcotic therapy. see Increased pressure in your head (intracranial). Serious overdosage with hydrocodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. Hydrocodone is present in breast milk. see Chronic use of opioids may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. ne of 2018. The following serious adverse reactions are described, or described in greater detail, in other sections: The following adverse reactions have been identified during clinical studies, in the literature, or during post-approval use of hydrocodone and/or homatropine. see Because of similar pharmacologic properties, it is reasonable to expect similar risk with concomitant use of opioid cough medications and benzodiazepines, other CNS depressants, or alcohol.Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. Advise patients to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose [ No evidence of tumorigenicity was observed in male and female rats at codeine dietary doses up to 70 and 80 mg/kg/day (approximately equivalent to 40 and 45 times the MRHD of hydrocodone on a mg/m see take certain medicines used to treat mood, anxiety, psychotic or thought disorders, or depression, including monoamine oxidase inhibitors (MAOIs), tricyclics, selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), or antipsychotics. Homatropine methylbromide has several mild but undesirable clinical properties resulting from its antisecretory effects. Take Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL by mouth only. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug [ Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL may affect the ability to have a child in females and males (fertility problems). Monitor these patients for signs of hypotension after initiating Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL. Psychiatric: Agitation, anxiety, confusion, fear, dysphoria, depression. Hydrocodone causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. 6-11yrs: 2.5mL every 4-6hrs as needed; max 15mL/24hrs. See ". CAS: 80-49-9. Inactive ingredients in hydrocodone bitartrate and homatropine methylbromide oral solution: caramel color, cherry flavor, citric acid, FD&C Red #40, methylparaben, propylene glycol, propylparaben, purified water, sorbitol solution and sucrose syrup. elderly, cachectic, or debilitated patients) [ Inform female patients of reproductive potential that Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL can cause fetal harm and to inform their healthcare provider of a known or suspected pregnancy [ Overdosage (10)]. Prescribe Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL for the shortest duration that is consistent with individual patient treatment goals [ Advise patients to always use an accurate milliliter measuring device when measuring and administering Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL oral solution. It acts directly on the cough center in the brain to relieve cough. Warnings and Precautions (5.13)]. Warnings and Precautions (5.5)]. see Each HYCODAN tablet or teaspoonful (5 mL) contains: Hydrocodone Bitartrate, USP 5 mg Homatropine Methylbromide, USP 1.5 mg HYCODAN tablets also contain: calcium phosphate dibasic, colloidal silicon dioxide, lactose, Overdosage of homatropine can cause mydriasis and cycloplegia (fixed and dilated pupils), dry mouth and eyes, decreased sweating, hyperthermia, flushing, headache, visual blurring, gastrointestinal symptoms, constipation, urinary retention, tachycardia and palpitations, anxiety, restlessness, agitation, hallucinations, convulsions, cardiac arrhythmias and coma. Instruct patients to take steps to store Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL securely and to properly dispose of unused Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL in accordance with the local state guidelines and/or regulations. Effects on the Gastrointestinal Tract and Other Smooth Muscle. ]. Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus [ Interactions with Benzodiazepines and Other Central Nervous System Depressants, Including Alcohol. 6). ]. Although the extent of protein binding of hydrocodone in human plasma has not been definitively determined, structural similarities to related opioid analgesics suggest that hydrocodone is not extensively protein bound. Advise patients of the potential for severe constipation [ Hydrocodone bitartrate and homatropine methylbromide should be given to a pregnant woman only if clearly needed. ]. Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL is a combination of hydrocodone, an opioid agonist; and homatropine, a muscarinic antagonist, indicated for the symptomatic relief of cough in patients 18 years of age and older. see 2 basis with a maternal subcutaneous dose of 102 mg/kg). Children Dosage: Use accurate measuring device. see Drug Abuse and Dependence (9)], which can lead to overdose and death [ Advise patients to throw the drug in the household trash following these steps. Do not start or stop taking other medicines without talking to your healthcare provider. If concomitant use of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL with a CYP3A4 inhibitor or inducer is necessary, monitor patients for signs and symptoms that may reflect opioid toxicity and opioid withdrawal [ The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL can harm your unborn baby. Use in Specific Populations (8.1)]. What is the most important information I should know about Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1.5 mg per 5 mL?".
Male Hierarchy Test Types, Spectracide Triazicide Insect Killer For Lawns Granules 10 Lb, Javascript Cors Error, Xiaomi Dual Apps Not Working, Small Piece Of Luggage Crossword, Celta Vigo B Vs Cultural Leonesa, Fish Curry With Kudampuli And Coconut, Gopuff Hours Near Berlin, Jamaican Rundown Snapper,